StockData
Vaxcyte, Inc. logo

Vaxcyte, Inc. (PCVX) stock

PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$59.40−2.21 (-3.59%)

Close on Nov 17, 2026Market cap $8.84BP/E –Yield 0.00%

Vaxcyte net income

Net income is the profit left for shareholders after every expense, interest and tax.

Vaxcyte's net income for the twelve months ending Jun 30, 2026 was -$1.06B. For fiscal 2025 it was -$766.63M. The highest annual figure on record is -$29.49M in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$766.63M–
FY2024Dec 31, 2024-$463.93M–
FY2023Dec 31, 2023-$402.27M–
FY2022Dec 31, 2022-$223.49M–
FY2021Dec 31, 2021-$100.08M–
FY2020Dec 31, 2020-$89.22M–
FY2019Dec 31, 2019-$50.27M–
FY2018Dec 31, 2018-$29.49M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$284.30M–
Q1 FY2026Mar 31, 2026-$320.62M–
Q4 FY2025Dec 31, 2025-$246.51M–
Q3 FY2025Sep 30, 2025-$212.83M–
Q2 FY2025Jun 30, 2025-$166.57M–
Q1 FY2025Mar 31, 2025-$140.72M–
Q4 FY2024Dec 31, 2024-$137.08M–
Q3 FY2024Sep 30, 2024-$103.12M–
Q2 FY2024Jun 30, 2024-$128.70M–
Q1 FY2024Mar 31, 2024-$95.02M–
Q4 FY2023Dec 31, 2023-$180.80M–
Q3 FY2023Sep 30, 2023-$92.66M–
Q2 FY2023Jun 30, 2023-$68.34M–
Q1 FY2023Mar 31, 2023-$60.46M–
Q4 FY2022Dec 31, 2022-$78.05M–
Q3 FY2022Sep 30, 2022-$57.92M–
Q2 FY2022Jun 30, 2022-$48.53M–
Q1 FY2022Mar 31, 2022-$38.99M–
Q4 FY2021Dec 31, 2021-$28.56M–
Q3 FY2021Sep 30, 2021-$26.62M–
Q2 FY2021Jun 30, 2021-$23.68M–
Q1 FY2021Mar 31, 2021-$21.22M–
Q4 FY2020Dec 31, 2020-$20.74M–
Q3 FY2020Sep 30, 2020-$21.02M–
Q2 FY2020Jun 30, 2020-$20.32M–
Q1 FY2020Mar 31, 2020-$27.14M–
Q4 FY2019Dec 31, 2019-$14.62M–
Q3 FY2019Sep 30, 2019-$11.32M–
Q2 FY2019Jun 30, 2019-$10.67M–
Q1 FY2019Mar 31, 2019-$13.67M–

More Vaxcyte figures

See a number that looks wrong?